Newsroom

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Media Center

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

February 5, 2019

Silicon Republic

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

February 5, 2019

Silicon Republic

This Scientist Is Building Custom Gene-Editing Tools

July 25, 2023

Forbes

Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners

July 20, 2023

Wall Street Journal

Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease

July 18, 2023

BioWorld

Sanofi expands collaboration with Scribe on CRISPR genome editing

July 18, 2023

Seeking Alpha

East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease

July 18, 2023

San Francisco Business Times

Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond

July 18, 2023

Fierce Biotech

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2026

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

July 27, 2026

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

July 23, 2026

Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials

June 18, 2026

Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 28, 2026

Publications

Sequential Proofreading Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

August 31, 2026

bioRxiv

Engineered Allosteric Control Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

January 14, 2026

bioRxiv

Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging

May 18, 2025

Journal of Controlled Release

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature